Interaction of natural products with cell survival and signaling pathways in the biochemical elucidation of drug targets in cancer

Future Oncology

Volumn 7, Issue 8, 2011, Pages 1007-1021

  Qurishi, Yasrib ^a   Hamid, Abid ^a   Majeed, Rabiya ^a   Hussain, Aashiq ^a   Qazi, Asif K ^a   Ahmed, Mudassier ^a   Zargar, Mohmmad Afzal ^b   Singh, Shashank Kumar ^a   Saxena, Ajit Kumar ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^b UNIVERSITY OF KASHMIR   (India)

Author keywords

biochemical pathway; drug target; epigenetics; histone deacetylase; inhibitor; kinase; natural product; proteasome; signaling

Indexed keywords

ALEMTUZUMAB; ALKALOID DERIVATIVE; ALPHA LACTALBUMIN; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BOMBESIN DERIVATIVE; BORTEZOMIB; CAROTENOID; CETUXIMAB; CHOLECYSTOKININ DERIVATIVE; CHOLESTEROL; ERLOTINIB; FLAVONOID; FLUOROURACIL; GASTRIN DERIVATIVE; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; LAPATINIB; LEXIDRONAM SAMARIUM SM 153; LIPID; METHOTREXATE; MONOCLONAL ANTIBODY; NATURAL PRODUCT; NEUROPEPTIDE Y DERIVATIVE; NITROGEN DERIVATIVE; ORGANOSULFUR DERIVATIVE; PANITUMUMAB; PEPTIDE DERIVATIVE; PHENOL DERIVATIVE; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; RADIOISOTOPE; RITUXIMAB; SALINOSPORAMIDE A; SOLID LIPID NANOPARTICLE; SORAFENIB; SUBSTANCE P DERIVATIVE; SUNITINIB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VINCA ALKALOID;

ACUTE LEUKEMIA; ANIMAL PRODUCT; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BACTERIAL INFECTION; BIOCOMPATIBILITY; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL SURVIVAL; CHEMICAL ANALYSIS; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFERTILITY; LYMPHOMA; MEDICINAL PLANT; NEOPLASM; PARASITOSIS; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REMISSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TOMOTHERAPY; TREATMENT RESPONSE; UBIQUITINATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AGENTS; CELL SURVIVAL; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 80051742943     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.69     Document Type: Review

References (50)

1. Drabu S, Khatri S, Babu S et al. Nanotechnology: An introduction to future drug delivery system. J. Chem. Pharm. Res. 2(1), 171-179 (2010).
2. Hirsch J. An anniversary for cancer chemotherapy. JAMA 296(12), 1518-1520 (2006). (Pubitemid 44465516)
3. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. (3), CD004064 (2010).
4. Malhotra P, Singh A. Nano medicine - a futuristic approach. JK Science 12, 3-5 (2010).
5. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7(6), 492-508 (2002). n Recent preclinical data suggest that the impact of intratumoral hypoxia, particularly in conjugation with an acidic environment, may be directly or indirectly mutagenic, thereby demonstrating that the strategy of overcoming hypoxia may be a viable and important approach. (Pubitemid 36008998)
6. Busch DB. Radiation and chemotherapy injury: Pathophysiology, diagnosis, and treatment. Crit. Rev. Oncol. Hematol. 15(1), 49-89 (1993). n The clinical use of radio- and chemo-therapy is essential for progress in research and care directed at the prevention, evaluation and treatment of cancer.
7. Deng JF. Clinical and laboratory investigations in herbal poisonings. Toxicology 27, 571-576 (2002).
8. Atkins HL, Mausner LF, Srivastava SC et al. Human biodistribution of Sn-117m (4+) DTPA; a new agent for palliative treatment of painful osseous metastases. Radiology 186, 279-283 (1993). (Pubitemid 23005502)
9. Liu SC, Minton NP, Giaccia AJ et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy 9, 291-296 (2002). (Pubitemid 34256904)
10. Lawrence JA, Forrest LJ. Intensity-modulated radiation therapy and helical tomotherapy: Its origin, benefits, and potential applications in veterinary medicine. Vet. Clin. North Am. Small Anim. Pract. 37(6), 1151-1165 (2007). (Pubitemid 47578460)
11. Epstein JA. Cardiac development and implications for heart disease. N. Engl. J. Med. 363, 17 (2010).
12. Jong MD, Breeman WA, Kwekkeboom DJ et al. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc. Chem. Res. 42(7), 873-880 (2009).
13. Dahanukar SA, Kulkarni RA. Pharmacology of medicinal plants and natural products. Indian J. Pharmacol. 32, S81-S118 (2000).
14. Rajamanickam S, Agarwal R. Cancer: Current status and future prospects. Drug Dev. Res. 69, 460-471 (2008).
15. Li JW-H, Vederas JC. Drug discovery and natural products: End of an era or an endless frontier? Science 325(5937), 161-165 (2009).
16. Kamatou GP, Makunga NP, Ramogola WP, Viljoen AM. Antimalarial and anticancer activities of selected South African Salvia species and isolated compounds from S. radula. S. Afr. J. Bot. 74 (2), 238-243 (2008). (Pubitemid 351484148)
17. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat. Prod. Rep. 17, 215-234 (2000). (Pubitemid 30390787)
18. Russo M, Mupo A, Spagnuolo C et al. Exploring death receptor pathways as selective targets in cancer therapy. Biochem. Pharmacol. 80(5), 674-682 (2010).
19. Lane AL, Moore BS. A sea of biosynthesis: Marine natural products meet the molecular age. Nat. Prod. Rep. 28, 411-428 (2011).
20. Tadmor B, Tidor B. Interdisciplinary research and education at the biology-engineering-computer science interface: A perspective. Drug Discov. Today 10(17), 1183-1189 (2005). nn Argues that interdisciplinary education and research models need to be innovative and reflect the needs and trends in the domains of healthcare and information technology. (Pubitemid 41327775)
21. Wender PA, Verma VA, Paxton TJ, Pillow TH. Function-oriented synthesis, step economy, and drug design. Acc. Chem. Res. 41(1), 40-49 (2008).
22. Goodman LS, Wintrobe MM, Dameshek W et al. Use of methyl-bis (b-chloroethyl) amine hydrochloride and tris (b-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. JAMA 105, 475-476 (1946).
23. Schwartsmann G, Da Rocha AB, Mattei J et al. Marine-derived anticancer agents in clinical trials. Expert Opin. Investig. Drugs 12(8), 1367-1383 (2003). (Pubitemid 36957792)
24. Doller A, Winkler C, Azrilian I et al. High constitutive HuR phosphorylation at Ser 318 by PKC d propagates tumor relevant functions in colon carcinoma cells. Carcinogenesis 32(5), 676-685 (2011).
25. Schor NF. Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol. Ther. 121(3), 253-264 (2009).
26. Chin YW, Balunas MJ, Chai HB et al. Drug discovery from natural sources. AAPS J. 8(2), E239-E253 (2006).
27. Pendergrass WR, Penn PE, Li J et al. Age-related telomere shortening occurs in lens epithelium from old rats and is slowed by caloric restriction. Exp. Eye Res. 73(2), 221-228 (2001). n Telomerase length and telomerase activity appear to be markers of the replicative history and proliferative potential of cells; the intriguing possibility remains that telomerase loss is genetically destructive. (Pubitemid 32977952)
28. Deweese JE, Burgin AB, Osheroff N. Human topoisomerase IIa uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res. 36(15), 4883-4893 (2008).
29. Heijden JV, Jong MC, Dijkmans B et al. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFa. Ann. Rheum. Dis. 63(2), 138-143 (2004). (Pubitemid 38122131)
30. Argyle DJ, Nasir L. Telomerase: A potential diagnostic and therapeutic tool in canine oncology. Vet. Pathol. 40, 1-7 (2003). (Pubitemid 38406108)
31. Blechner MD, Mandavilli SR, Tsongalis GJ. Measuring telomerase activity for the early detection of cancer. Conn. Med. 65(11), 643-648 (2001). (Pubitemid 33627546)
32. Urquidi V, Tarin D, Goodison S. Telomerase in cancer: Clinical applications. Ann. Med. 30, 419-430 (1998). (Pubitemid 28479489)
33. Shin S, Hong A, Solomon MJ, Lee CS. The role of telomeres and telomerase in the pathology of human cancer and aging. Pathology 38(2), 103-113 (2006).
34. Yang Y, Kitagaki J, Wang H et al. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 100(1), 24-28 (2009).
35. Qiu XB, Goldberg AL. Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc. Natl Acad. Sci. USA 99(23), 14843-14848 (2002). (Pubitemid 35334571)
36. Pray TR, Parlati F, Huang J et al. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist. Updat. 5(6), 249-258 (2002). (Pubitemid 36132806)
37. Schilsky RL, Gordon G, Gilmer TM. The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin. Cancer Res. 14, 5685-5691 (2008). nn Attempts to review some medicinal plants as inhibitors for the prevention and treatment of various targets in cancer. Plant-derived compounds have played an important role in the development of several clinically useful anticancer agents.
38. Kuhn DJ, Chen Q, Peter VM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110(9), 3281-3290 (2007). (Pubitemid 350106321)
39. Rajkumar SV, Richardson PG, Hideshima T et al. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23(3), 630-639 (2005). (Pubitemid 46224241)
40. Son H, Chung Yang HD et al. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg. Med. Chem. Lett. 17, 4753-4755 (2007).
41. Lin HY, Chen CS, Lin SP et al. Targeting histone deacetylase in cancer therapy. Med. Res. Rev. 26(4), 397-413 (2006).
42. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003). (Pubitemid 37448928)
43. Jason B, Luke W. Hsp90: An emerging target for breast cancer therapy. Anticancer Drugs 15(7), 651-662 (2004).
44. Bolde JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 11(9), 769-784 (2006). nn Identification of potent histone deacetylase inhibitors has been considered to be a very intriguing approach for the development of cancer chemotherapy. (Pubitemid 44348499)
45. Raschke RA, Gollihare B, Wunderlich TA et al. A computer alert system to prevent injury from adverse drug events, development and evaluation in a community teaching hospital. JAMA 280, 1317-1320 (1998). (Pubitemid 28473717)
46. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Focus on acetylation: The role of histone deacetylase inhibitors in cancer therapy and beyond. Expert Opin. Investig. Drugs 16(5), 569-571 (2007). (Pubitemid 46723267)
47. Loganzo F, Discafani CM, Annable T et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents p-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 63, 1838-1845 (2003). nn Identification of a large number of targets has uncovered new players that are involved in disassembly of microtubules. (Pubitemid 36460846)
48. Breen EC, Walsh J. Tubulin-targeting agents in hybrid drugs. Curr. Med. Chem. 17(31), 609-639 (2010).
49. Thomas ES, Gomez HL, Li RK. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25(33), 5210-5217 (2007). (Pubitemid 350232252)
50. Zhu T, Gu J, Yu K et al. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft model. J. Med. Chem. 49(4), 1373-1378 (2006). (Pubitemid 43271889)